Sylvie K. Sakata
Pfizer (United States)(US)Université Bourgogne Franche-Comté(FR)PRX Research
Publications by Year
Research Areas
Chemical Synthesis and Analysis, SARS-CoV-2 and COVID-19 Research, Monoclonal and Polyclonal Antibodies Research, Computational Drug Discovery Methods, Catalytic C–H Functionalization Methods
Most-Cited Works
- → Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 6. Structure−Activity Studies of Orally Bioavailable, 2-Pyridone-Containing Peptidomimetics(2002)142 cited
- → Introduction of a Crystalline, Shelf-Stable Reagent for the Synthesis of Sulfur(VI) Fluorides(2018)136 cited
- → Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 8. Pharmacological Optimization of Orally Bioavailable 2-Pyridone-Containing Peptidomimetics(2003)115 cited
- → JUMP Cell Painting dataset: morphological impact of 136,000 chemical and genetic perturbations(2023)97 cited
- → A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19(2024)61 cited
- → Asymmetric Total Synthesis of Batzelladine D(1999)60 cited
- → Discovery of SARS-CoV-2 papain-like protease (PL pro ) inhibitors with efficacy in a murine infection model(2024)42 cited
- → Characterization of Specific N -α-Acetyltransferase 50 (Naa50) Inhibitors Identified Using a DNA Encoded Library(2020)35 cited
- → Quick Building Blocks (QBB): An Innovative and Efficient Business Model To Speed Medicinal Chemistry Analog Synthesis(2019)31 cited
- → Construction of Substituted Cyclohexanones by Reductive Cyclization of 7-Oxo-2,8-alkadienyl Esters(2001)28 cited